Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial

Abebaw Fekadu, Miraf Mesfin, Girmay Medhin, Atalay Alem, Solomon Teferra, Tsehaysina Gebre-Eyesus, Teshale Seboxa, Abraham Assefa, Jemal Hussein, Martha T Lemma, Christina Borba, David C Henderson, Charlotte Hanlon, Teshome Shibre, Abebaw Fekadu, Miraf Mesfin, Girmay Medhin, Atalay Alem, Solomon Teferra, Tsehaysina Gebre-Eyesus, Teshale Seboxa, Abraham Assefa, Jemal Hussein, Martha T Lemma, Christina Borba, David C Henderson, Charlotte Hanlon, Teshome Shibre

Abstract

Background: Schizophrenia is understood to be a heterogeneous brain condition with overlapping symptom dimensions. The negative symptom dimension, with its protean cognitive manifestations, responds poorly to treatment, which can be a particular challenge in countries where clozapine therapy is not available. Preliminary data indicate that minocycline may be beneficial adjunct in the treatment of schizophrenia: positive, negative, and cognitive symptoms.In this study we aim to assess the efficacy of adjunctive minocycline to alleviate symptoms of schizophrenia in patients who have failed to respond to a therapeutic trial of antipsychotic medications.

Methods: The study is a parallel group, double-blind, randomized, placebo-controlled trial. Participants will be adults (aged 18 years and above) with first episode or relapse episode of schizophrenia of under 5 years' duration. Patients who failed to show adequate therapeutic response to at least one antipsychotic medication given for a minimum of 4 weeks will be recruited from a psychiatry hospital in Addis Ababa and a psychiatry clinic in Butajira, Ethiopia. A total of 150 participants (75 in each arm) will be required to detect a five-point mean difference between the intervention arms adjusting for baseline symptom severity, at 90% power and 95% confidence. Patients in the intervention arm will receive minocycline (200 mg/day orally) added on to the regular antipsychotic medications participants are already on. Those in the placebo arm will receive an inactive compound identical in physical appearance to minocycline. Intervention will be offered for 12 weeks. Diagnosis will be established using the operational criteria for research (OPCRIT). Primary outcome measure will be a change in symptom severity measured using the positive and the negative syndrome scale for schizophrenia (PANSS). Secondary outcome measures will include changes in severity of negative symptoms, proportion achieving remission, and level of functioning. Whether changes are maintained post intervention will also be measured (PANSS). Key assessment for the primary outcome will be conducted at the end of trial (week 12). One post-intervention assessment will be conducted 4 weeks after the end of intervention (week 16) to determine sustainability of change.

Trial registration: Clinicaltrials.gov identifier: NCT01809158.

Figures

Figure 1
Figure 1
Adjunctive minocycline versus placebo: a trial flow diagram.

References

    1. Rupp A, Keith SJ. The costs of schizophrenia. Psychiatr Clin N Am. 1993;16:413–423.
    1. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings and mechanisms. Arch Gen Psychiatry. 1995;52:341–351. doi: 10.1001/archpsyc.1995.03950170015003.
    1. Stover EL, Brady L, Marder SR. New paradigms for treatment development. Schizophr Bull. 2007;33:1093–1099. doi: 10.1093/schbul/sbm085.
    1. May PRA. Treatment of schizophrenia. New York: Science House; 1968.
    1. Rosenheck RA, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsaio J, Lieberman J. Barriers to employment for people with schizophrenia. Am J Psychiatr. 2006;163:411–417. doi: 10.1176/appi.ajp.163.3.411.
    1. Rosenheck RA, Perlick D, Bingham S, Liu-Mares, Collins J, Warren S, Leslie D. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA. 2003;290:2693–2702. doi: 10.1001/jama.290.20.2693.
    1. Essock SM, Frisman LK, Covell NH, Hargreaves W. Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in state hospitals. Arch Gen Psychiatry. 2000;57:987–994. doi: 10.1001/archpsyc.57.10.987.
    1. Rosenheck RA, Cramer J, Xu W, Thomas J, Henderson W, Frisman LK, Fye C, Charney D. A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337:809–815. doi: 10.1056/NEJM199709183371202.
    1. Brunton LL, Parker KL. Goodman & Gilman’s manual of pharmacology and therapeutics. New York: McGraw Hill; 2008.
    1. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918–934. doi: 10.1016/j.cell.2010.02.016.
    1. Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs. 2012;26:391–401. doi: 10.2165/11632000-000000000-00000.
    1. Zhang L, Shirayama Y, Iyo M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2007;32:2004–2010. doi: 10.1038/sj.npp.1301313.
    1. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007;1154:154–162.
    1. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67:1442–1448. doi: 10.1001/archneurol.2010.191.
    1. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008;31:287–292. doi: 10.1097/WNF.0b013e3181593d45.
    1. Won SJ, Kim JH, Yoo BH, Sohn M, Kauppinen TM, Park M, Kwon H, Liu J, Suh SW. Prevention of hypoglycemia-induced neuronal death by minocycline. J Neuroinflammation. 2012;9:225. doi: 10.1186/1742-2094-9-225.
    1. Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galind MF. Minocycline and cytoprotection: sheddidng new light on a shadowy controversy. Curr Drug Deliv. 2007;4:225–231. doi: 10.2174/156720107781023938.
    1. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist. 2005;11:308–322. doi: 10.1177/1073858405275175.
    1. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates signicant recovery from spinal cord injury in mice. Brain. 2003;126:1628–1637. doi: 10.1093/brain/awg178.
    1. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:304–307. doi: 10.1016/j.pnpbp.2006.08.013.
    1. Chaves C, Marque CR, Chaudhry IB, Hussain N, Minhas FA, Oliveria JP. Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia. Schizophr Bull. 2009;35:354.
    1. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets. 2008;7:376–381. doi: 10.2174/187152708786441858.
    1. Chaudhry IB, Hussain N, Hallak J, Minhas FA, Dursun SM, Richardson P. Preventing clinical deterioration in first episode psychosis: potential role of minocycline in neruoprotection. Biol Psychiatry. 2009;64:915.
    1. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138–149. doi: 10.4088/JCP.08m04666yel.
    1. Fekadu A, Desta M, Alem A, Prince M. A descriptive analysis of admissions to amanuel psychiatric hospital in Ethiopia. Ethiop J Health Dev. 2007;21:173–178.
    1. Alem A, Kebede D, Fekadu A, Shibre T, Fekadu D, Beyero T, Medhin G, Negash A, Kullgren G. Clinical course and outcome of schizophrenia in a predominantly treatment naïve cohort in Ethiopia. Schizophr Bull. 2009;35:646–654. doi: 10.1093/schbul/sbn029.
    1. Fekadu A, Kebede D, Alem A, Fekadu D, Mogga S, Negash A, Medhin G, Beyero T, Shibre T. Clinical outcome in bipolar disorder in a community-based follow-up study in Butajira-Ethiopia. Acta Psychiatr Scand. 2006;114:426–434. doi: 10.1111/j.1600-0447.2006.00825.x.
    1. Kebede D, Alem A, Shibre T, Negash A, Fekadu A, Fekadu D, Deyassa N, Jacobsson L, Kullgren G. Onset and clinical course of schizophrenia in Butajira-Ethiopia-a community-based study. Soc Psychiatry Psychiatr Epidemiol. 2003;38:625–631. doi: 10.1007/s00127-003-0678-4.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4. Washington, DC: American Psychiatric Association; 1994.
    1. Leucht S, Kane JM, Kissing W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79:231–238. doi: 10.1016/j.schres.2005.04.008.
    1. Shibre T, Alem A, Abdulahi A, Araya M, Beyero T, Medhin G, Deyassa N, Negash A, Fekadu A. Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized placebo-controlled clinical trial. Schizophr Bull. 2010;36:846–851. doi: 10.1093/schbul/sbn191.
    1. McGuffin P, Farmer AE, Harvey I. A Polydiagnostic application of operational criteria in studies of psychotic Illness: development and reliability of the OPCRIT System. Arch Gen Psychiatry. 1991;48:764–770. doi: 10.1001/archpsyc.1991.01810320088015.
    1. World Health Organization. Schedules for clinical assessment in neuropsychiatry. Version 2.1. Geneva: WHO; 1997.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261.
    1. Kay SR, Opler LA, Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry. 1986;149:439–448. doi: 10.1192/bjp.149.4.439.
    1. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenia. Psychiatry Res. 1988;23:99–110. doi: 10.1016/0165-1781(88)90038-8.
    1. Mortimer AM. Symptom rating scale and outcome in schizophrenia. Br J Psychiatry. 2007;191:7–14. doi: 10.1192/bjp.191.50.s7.
    1. Sajatovic M, Ramirez LF. Rating scales in mental health. 2. Hudson (Cleveland): Lexi-Comp; 2006.
    1. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr. 2005;162:441–449. doi: 10.1176/appi.ajp.162.3.441.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit